The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A UK-based phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.
N. M. Steven
No relevant relationships to disclose
K. J. Harrington
No relevant relationships to disclose
L. Lee
No relevant relationships to disclose
H. Jia
No relevant relationships to disclose
M. K. Tanday
No relevant relationships to disclose
C. Roberts
No relevant relationships to disclose
C. Edwards
No relevant relationships to disclose
L. McGuigan
No relevant relationships to disclose
A. G. J. Hartley
No relevant relationships to disclose
M. Viskaduraki
No relevant relationships to disclose
E. P. Hui
No relevant relationships to disclose
A. T. C. Chan
No relevant relationships to disclose
A. B. Rickinson
No relevant relationships to disclose
G. S. Taylor
No relevant relationships to disclose